1428341-13-2

Usage

Uses

Used in Pharmaceutical Industry:
Tert-butyl trans-4-amino-3-methylpiperidine-1-carboxylate is used as a reagent for the preparation of chiral, broad-spectrum antimicrobial 7-substituted piperidino-quinolone carboxylic acid derivatives. These derivatives exhibit potent antimicrobial activity against a wide range of bacteria, making them valuable in the development of new antibiotics to combat drug-resistant infections.

Upstream product

• 3886-69-9 (R)-1-phenyl-ethyl-amine 
• 181269-69-2 tert-butyl 3-methyl-4-oxopiperidine-1-carboxylate 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 723308-57-4 (3S,4S)-3-methyl-4-(1-(R)-phenyl-ethylamino)-piperidine-1-carboxylic acid tert-butyl ester 
• 723308-56-3 (3R,4R)-3-methyl-4-(1-(S)-phenyl-ethylamino)-piperidine-1-carboxylic acid tert-butyl ester 

Downstream Products

• 1186230-35-2 (rac)-(cis/trans)-N-(3-methyl-piperidin-4-yl)-2-phenyl-acetamide 
• 396133-35-0 3-methylpiperidin-4-amine 

Relevant academic research and scientific papers

PHENYL AMINO PIPERIDINE mTORC INHIBITORS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same.

SUBSTITUTED PIPERIDINE COMPOUNDS

The present disclosure provides substituted piperidine compounds having Formula (I), and the pharmaceutically acceptable salts and solvates thereof, wherein R1, B, X, and Z are defined as set forth in the specification. The present disclosure i

4,6-DIAMINONICOTINAMIDE COMPOUND

[Problem] The present invention provides a 4,6-diaminonicotinamide compound which is useful as an active ingredient of a pharmaceutical composition, in particular, a pharmaceutical composition for treating diseases caused by undesirable and/or abnormal cytokine signal transduction. [Means for Solution] The present inventors have extensively studied compounds having a JAK3 inhibitory action, and as a result, they have found that a 4,6-diaminonicotinamide compound which is the compound of the present invention has an excellent JAK3 inhibitory action and is useful as an agent for preventing or treating diseases caused by undesirable and/or abnormal cytokine signal transduction, thereby completing the present invention.

NOVEL HETEROCYCLIC CARBOXAMIDES AS M1 AGONISTS

The present invention relates to novel M1 agonistic compounds of formula (I) and their use in the treatment of cognitive impairment associated i.a. with schizophrenia and in the treatment of other diseases mediated by the muscarinic M1 receptor.

COMPOUNDS WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE

Compounds of formula (I) or a salt thereof are provided: (I) wherein R4, R5, R6, Q and R are as defined in the description. Uses of the compounds as medicaments and in the manufacture of medicaments for treating psychotic

CCR8 INHIBITORS

Disclosed are CCR8 inhibitors represented by Structural Formulas (I). The variables in Structural Formula (I) are described herein. Also disclosed are methods of treating a subject with a CCR8 mediated condition, especially asthma, by administering one of the disclosed CCR8 inhibitors to the subject.

CCR8 INHIBITORS

Disclosed is an inhibitor of CCR8 that is represented by Structural Formula (I). Also disclosed are pharmaceutical compositions comprising a pharmaceutically acceptable carrier or diluent and a CCR8 inhibitor represented by Structural Formula (I). Also disclosed is a method of treating inflammatory disorders in a subject by administering a CCR8 inhibitor to the subject.